In phase I clinical trials of AD, stable expression of nerve growth factor (NGF) in the patient's brain was successfully achieved through bilateral stereotactic injections into the nucleus basalis of Meynert in the forebrain of AD (Hudry and Vandenberghe, 2019; Rafii et al., 2014). The gene discussed is NGF; the disease is Alzheimer disease.